Search company, investor...

Predict your next investment

Abcam company logo
Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
abcam.com

Partners & Customers

10

Service Providers

2

About Abcam

Abcam (NASDAQ: ABCM) supplies products in research areas such as cancer, cardiovascular, chromatin and nuclear signaling, immunology, neuroscience, and stem cells. The company provides a range of non-primary antibody products such as secondary antibodies, kits, proteins, peptides, and lysates. It was founded in 1998 and is based in Cambridge, United Kingdom.

Headquarters Location

Discovery Drive Cambridge Biomedical Campus

Cambridge, England, CB2 0AX,

United Kingdom

888-772-2226

Want to inform investors similar to Abcam about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Abcam News

The Rales Brothers Are Doing It Again: How They Turned Danaher Into A Spinoff Machine

Sep 23, 2023

Washington, DC. Steven M. Rales is an American businessman and film producer, and chairman of Danaher Corporation. He is listed as the 118th richest person in America, with a value of $3.2 billion. Raised in a Jewish family, Rales is one of four sons of Norman and Ruth Rales. His father was raised in an orphanage, the Hebrew Orphan Asylum in New York City and later became a businessman who sold his bui (Photo by Mark Reinstein/Corbis via Getty Images) Corbis via Getty Images The Rales brothers, Steven M. Rales and Mitchell P. Rales, are renowned American businessmen and investors who have left an indelible mark on the corporate landscape, primarily through their association with Danaher Corporation. Their journey to prominence began in the 1980s, when they, along with a group of investors, acquired Danaher, a struggling conglomerate. Under their astute leadership, the company underwent a remarkable transformation, evolving into a highly successful, diversified industrial giant. The Rales brothers are celebrated for their disciplined and strategic approach to business. They have consistently sought out industrial and technology companies with substantial growth potential, instilling principles of lean manufacturing and continuous improvement inspired by the Japanese concept of Kaizen. Their influence led Danaher to diversify into various sectors, including healthcare, life sciences, diagnostics, and environmental solutions. In 2015, they made a significant strategic move by splitting Danaher into two separate entities: Danaher Corporation, focusing on science and technology, and Fortive Corporation, centered on industrial technology. This restructuring allowed each company to concentrate more effectively on its distinct market opportunities. Beyond their business acumen, the Rales brothers are known for their philanthropic endeavors, supporting various causes, including the arts and education. Their wealth and business achievements have consistently earned them a place on Forbes' list of the wealthiest Americans. In essence, the Rales brothers' legacy lies in their ability to steer companies towards success, their commitment to philanthropy, and their enduring impact on the corporate world. UKRAINE - 2021/05/24: In this photo illustration, Danaher Corporation logo is seen displayed on a ... [+] smartphone and pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images MORE FOR YOU In the annals of business and finance, the Rales brothers emerged as figures of profound success, and yet, they were known for their propensity for discretion. Their narrative, a tale of exceptional accomplishment, was enshrouded in an aura of secrecy, a facet that perpetually piqued the curiosity of those seeking insights into their methodologies and motivations. These two brothers, renowned for orchestrating transformative changes, had undertaken the stewardship of Danaher Corporation, a struggling conglomerate, and masterminded its evolution into a global industrial juggernaut. However, amid their substantial influence and wealth, the Rales brothers remained conspicuously private individuals. Though their footprint could be discerned within the realm of commerce, details pertaining to their personal lives remained elusive. It was postulated that their unassuming demeanor mirrored their modus operandi in business: unobtrusive, methodical, and concentrated. Whereas many individuals occupying their stature often gravitated toward the limelight, the Rales brothers opted to let their actions and outcomes resound more emphatically than their verbal pronouncements. The veil of secrecy enveloping them lent an air of intrigue to their narrative. Some conjectured that their predilection for discretion was a tactical maneuver, affording them the freedom to operate behind the scenes, unburdened by the scrutiny that typically accompanies individuals of high-profile status. Others perceived it as a manifestation of their reverence for the craft of business itself, wherein outcomes trumped ostentation. Ultimately, the chronicle of the Rales brothers underscored the notion that triumph could be attained with quietude, away from the public gaze. Their proclivity for secrecy heightened the allure of their journey, leaving those who endeavored to decipher their enigma with a sense of wonderment and fascination. Thus, the enigmatic legacy of the Rales brothers persisted in its capacity to captivate the imagination of the business domain. The Kaizen Philosophy Danaher Corporation designs, manufactures, and markets medical, industrial, and commercial products and services from its headquarters in Washington, D.C. It has historically attempted to keep a minimal public profile and has grown primarily through acquisitions. Danaher was one of the first companies to implement the Kaizen philosophy. Kaizen principles to manufacturing, which is a lean manufacturing Japanese philosophy of continuous improvement and elimination of waste. Kaizen, a Japanese term for "continuous improvement," is a management philosophy and practice focused on making incremental, small-scale enhancements to processes, products, and systems to achieve continuous and sustainable progress. Originating in Japan after World War II, it emphasizes the idea that even modest changes can lead to substantial improvements over time. Key principles of Kaizen include waste elimination, standardization, employee involvement, and the pursuit of continuous, manageable improvements. Kaizen events, or "blitzes," are often used to drive quick results by mobilizing cross-functional teams to address specific issues or process improvements. The Plan-Do-Check-Act (PDCA) cycle is a fundamental concept, guiding organizations to plan changes, implement them, check results, and act to make further refinements based on feedback. The benefits of Kaizen include improved efficiency, enhanced quality, cost reduction, and increased employee engagement. While it originated in manufacturing, Kaizen has been successfully applied in diverse sectors such as healthcare, software development, and services. Kaizen's long-term commitment to continuous improvement and its global influence make it a cornerstone of modern management practices, contributing to better processes, products, and outcomes in organizations worldwide. Spinoffs As A Key Value Creator Value creation though Spinoff is a strategic corporate action that involves separating a subsidiary or division from a parent company, resulting in two distinct, independently traded entities. Completely in line with the brothers’ vision of continuous improvement in their businesses, focusing on core competencies and improved operational efficiency. They have been active. Danaher Value Creation Through Spinoffs Edge Consulting Group The Latest Spinoff DHR is set to transform into a pure healthcare player consisting of its diagnostics, life science, and biotechnology businesses. The Spinoff of the Environmental & Applied Solutions (EAS) division (Veralto) will pave the way for DHR to become a fully integrated vertical healthcare chain provider. Although recent guidance from management indicates a subdued outlook for FY23 due to macroeconomic challenges, inventory adjustments, and cautious demand, it is anticipated that pent-up demand will alleviate these issues and gain momentum starting in Q1 FY24. Meanwhile, its modest leverage of ~1.1x and strong cash flow allow it to grow inorganically by strategically deploying its capital, thereby strengthening its product offering, as evident from its recent acquisition announcement of Abcam for $5.7bn. Danaher Value Creation

Abcam Acquisitions

11 Acquisitions

Abcam acquired 11 companies. Their latest acquisition was BioVision on August 02, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/2/2021

$99M

Acquired

5

3/4/2020

Grant

$99M

$0.1M

Acquired

1

1/30/2020

$99M

Acquired Unit

1

11/11/2019

Subscribe to see more

$99M

Subscribe to see more

10

11/11/2019

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/2/2021

3/4/2020

1/30/2020

11/11/2019

11/11/2019

Investment Stage

Grant

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$0.1M

Note

Acquired

Acquired

Acquired Unit

Subscribe to see more

Subscribe to see more

Sources

5

1

1

10

10

Abcam Partners & Customers

10 Partners and customers

Abcam has 10 strategic partners and customers. Abcam recently partnered with NanoString Technologies on November 11, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

11/9/2022

Licensee

United States

NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research

SEATTLE & CAMBRIDGE , United Kingdom -- -- NanoString Technologies , Inc. , a leading provider of life science tools for discovery and translational research , and Abcam , a global life science company working together with researchers to advance science and enable faster breakthroughs , today announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString Technologies , Inc. 's high-plex spatial multiomic solutions .

4

2/1/2022

Partner

United States

Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications

Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform , and Abcam , a global innovator in life sciences reagents and tools , today announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery , development and commercialization for diagnostic and research applications .

3

1/4/2022

Partner

United States

Alamar Biosciences partners with Abcam to drive understanding of the human proteome

FREMONT , Calif. and CAMBRIDGE , England , Jan. 4 , 2022 / PRNewswire / -- Alamar Biosciences , a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases , and Abcam , a global innovator in life sciences research tools , today announced a strategic partnership to further understanding of the human proteome .

5

11/2/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

10/28/2021

Client

China

Subscribe to see more

Subscribe to see more

10

Date

11/9/2022

2/1/2022

1/4/2022

11/2/2021

10/28/2021

Type

Licensee

Partner

Partner

Partner

Client

Business Partner

Country

United States

United States

United States

United States

China

News Snippet

NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research

SEATTLE & CAMBRIDGE , United Kingdom -- -- NanoString Technologies , Inc. , a leading provider of life science tools for discovery and translational research , and Abcam , a global life science company working together with researchers to advance science and enable faster breakthroughs , today announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString Technologies , Inc. 's high-plex spatial multiomic solutions .

Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications

Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform , and Abcam , a global innovator in life sciences reagents and tools , today announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery , development and commercialization for diagnostic and research applications .

Alamar Biosciences partners with Abcam to drive understanding of the human proteome

FREMONT , Calif. and CAMBRIDGE , England , Jan. 4 , 2022 / PRNewswire / -- Alamar Biosciences , a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases , and Abcam , a global innovator in life sciences research tools , today announced a strategic partnership to further understanding of the human proteome .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

3

5

10

10

Abcam Service Providers

2 Service Providers

Abcam has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

IPO

Investment Bank

Bookrunner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

IPO

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Bookrunner

Subscribe to see more

Partnership data by VentureSource

Abcam Team

7 Team Members

Abcam has 7 team members, including , .

Name

Work History

Title

Status

David Cleevely

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

David Cleevely

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Abcam to Competitors

Nuclera Logo
Nuclera

Nuclera provides researchers with a desktop bioprinter capable of producing genes and proteins. Its bioprinter aims to allow researchers to accelerate discoveries and treatments by delivering on-demand desktop access. The company was founded in 2013 and is based in Cambridge, U.K.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.